Open AccessImproving seasonal and pandemic influenza vaccines
Author(s) -
Saville Melanie,
Marsh Grenville,
Hoffenbach Agnes
Publication year - 2008
Publication title -
influenza and other respiratory viruses
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.743
H-Index - 57
eISSN - 1750-2659
pISSN - 1750-2640
DOI - 10.1111/j.1750-2659.2008.00060.x
Subject(s) - pandemic , seasonal influenza , vaccination , live attenuated influenza vaccine , immunogenicity , virology , human mortality from h5n1 , pandemic influenza , influenza vaccine , medicine , covid-19 , immunology , environmental health , antigen , infectious disease (medical specialty) , disease , pathology
Challenges facing seasonal and pandemic influenza vaccination include: increasing the immunogenicity of seasonal vaccines for the most vulnerable, increasing vaccination coverage against seasonal influenza, and developing vaccines against pandemic strains that are immunogenic with very low quantities of antigen to maximize the number of people who can be vaccinated with a finite production capacity. We review Sanofi Pasteur’s epidemic and pandemic influenza research and development programmes with emphasis on two key projects: intradermal influenza vaccine for seasonal vaccination of both elderly and younger adults, and pandemic influenza vaccine.